Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus WOLFINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus WOLFINA.
ENSKYCE vs WOLFINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Not specified in available data; likely unapproved or investigational drug.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
Initial: 50 mg orally twice daily. Titrate to 100 mg twice daily after 2 weeks based on tolerability.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Primarily renal (70% unchanged), with 20% biliary/fecal and 10% metabolic degradation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive